thiazolidinedione衍生物:在癌症治疗中新兴的作用
Ganesh Latambale1, Kapil Juvale2
1Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai, India.
Molecular diversity
|February 3, 2025
概括
铁二衍生物通过向关键癌症途径,显示出作为抗癌药物的前景. 这些化合物为癌症治疗提供了潜在的改善,包括增强免疫疗法和化疗疗效.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症是全球首要的死亡原因,化疗通常由于缺乏瘤细胞选择性而导致严重的副作用.
- 改进的癌症治疗方法对于克服当前治疗限制和降低患者死亡率至关重要.
- 主要用于治疗2型糖尿病的thiazolidinedione衍生物正在成为潜在的抗癌药物.
研究的目的:
- 审查 thiazolidinedione衍生物的抗癌潜力.
- 探索它们调节参与致癌的关键分子通路的能力.
- 检查它们在各种癌症类型中的有效性以及它们在组合疗法中的作用.
主要方法:
- 在癌症治疗中对 thiazolidinedione衍生物进行临床前和临床研究的审查.
- 对它们的作用机制的分析,包括对细胞增殖,细胞亡,血管新生和特定激酶的影响.
- 检查它们的抗炎,抗氧化和抗增殖特性,特别是通过PPARγ激活.
主要成果:
- thiazolidinediones 通过激活 PPARγ 在乳腺癌,结肠癌和前列腺癌中表现出抗增殖作用.
- 这些化合物调节关键癌症通路,如Raf激酶,EGFR,HER-2,HDAC和COX-2.
- 有证据表明,有可能提高免疫疗法和化疗的疗效.
结论:
- 铁二衍生物作为抗癌剂具有显著的治疗潜力.
- 了解它们的结构-活动关系和分子机制是优化它们使用的关键.
- 为了改善癌症治疗结果,需要对其安全性和临床转化进行进一步的研究.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
162
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
525
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
525
01:23Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
01:17Oral Hypoglycemic Agents: Sulfonylureas
184
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
184
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
215
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
215
01:24Glucagon-like Receptor Agonists
292
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
292